TScan Therapeutics (TCRX) Current Leases (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Current Leases data on file, last reported at $7.4 million in Q1 2026.

• On a quarterly basis, Current Leases rose 49.63% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 49.63% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, up 56.83% from the prior year.
• Current Leases for Q1 2026 stood at $7.4 million, up from $7.2 million in the prior quarter.
• Over the last five years, Current Leases for TCRX reached as high as $7.4 million in Q1 2026 and fell as low as $1.7 million in Q1 2022.
• Historically, Current Leases has averaged $4.3 million across 5 years, with a median of $3.9 million in 2024.
• Across the five-year window, Current Leases jumped 143.79% in 2023 and fell 14.14% in 2024, its largest moves.
• Year by year, Current Leases stood at $3.7 million in 2022, then fell by 11.82% to $3.2 million in 2023, then surged by 40.79% to $4.6 million in 2024, then surged by 56.83% to $7.2 million in 2025, then rose by 3.78% to $7.4 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $7.4 million in Q1 2026, $7.2 million in Q4 2025, and $6.9 million in Q3 2025.